1. "Population Sciences Research Program"
Formats
  1. Journal Article (7144)
  2. Meeting Abstract (3307)
  3. Book Section (330)
  4. Review (289)
  5. Editorial (253)
  6. Research Letter (116)
  7. Correspondence (111)
  8. Conference Paper (67)
  9. Guidelines (59)
  10. Miscellaneous (41)
  11. Book Whole (24)
Groups
  1. Population Sciences Research Program (11741)
  2. Survivorship Research (5670)
  3. Department of Medicine (5135)
  4. Epidemiology and Biostatistics (4867)
  5. Solid Tumor Oncology Division (3334)
  6. Surgery (2966)

More Groups

People
  1. Andrew Vickers (880)
  2. Kenneth Offit (788)
  3. Mark Robson (676)
  4. Steven Horwitz (645)
  5. T Peter Kingham (609)
  6. Katherine Panageas (512)

More People

Years
  1. 2025 (236)
  2. 2024 (722)
  3. 2023 (821)
  4. 2022 (828)
  5. 2021 (786)
  6. 2020 (738)

More Years

Publications
  1. Journal of Clinical Oncology (1246)
  2. Blood (374)
  3. Psycho-Oncology (347)
  4. Cancer (240)
  5. Cancer Research (234)
  6. Annals of Surgical Oncology (233)

More Publications

Publishers
  1. American Society of Clinical Oncology (1412)
  2. Elsevier Inc. (1128)
  3. Springer (1112)
  4. Elsevier Science, Inc. (816)
  5. Oxford University Press (753)
  6. Wiley Blackwell (614)

More Publishers

Results (11741)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Correlates of work status during adjuvant chemo- or radiation therapy for breast cancer
    Meeting Abstract

    Blinder, V. S.; Eberle, C. E.; Patil, S.; Oeffinger, K. C.; Bradley, C.; Gany, F.
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Changes in body composition and prognostic importance of sarcopenia in patients receiving CTRT for oropharyngeal cancer
    Meeting Abstract

    Baxi, S. S.; Jones, L.; Eaton, A.; Gandelman, S.; Halpenny, D.; Jackson, J.; Kurtzman, R.; McBride, S. M.; Plodkowski, A.; Pfister, D. G.
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Systematic review of overuse in oncology
    Meeting Abstract

    Baxi, S. S.; Kale, M.; Roman, B. R.; Yang, A.; Derosa, A.; Kim, A.; Keyhani, S.; Korenstein, D.
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Identification of genetic test results with conflicting interpretations in prospective registry of multiplex testing (PROMPT)
    Meeting Abstract

    Balmana, J.; Digiovanni, L.; Gaddam, P.; Walsh, M. F.; Garber, J. E.; Couch, F. J.; Offit, K.; Robson, M. E.; Domchek, S. M.
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Prevalence, risk factors, and sequelae of long-term chemotherapy-induced peripheral neuropathy (CIPN) among breast cancer survivors
    Meeting Abstract

    Bao, T.; Li, S. Q.; Mao, J. J.
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Exercise training reduces splenic accumulation of MDSCs and delays tumor progression in a therapeutic breast cancer model
    Meeting Abstract

    Wennerberg, E.; Schwitzer, E.; Lhuillier, C.; Koelwyn, G.; Hiner, R.; Jones, L.; Demaria, S.
    Journal for ImmunoTherapy of Cancer (2016)

    Fulltext@MSK | Save
  • Preoperative consent for patients with limited English proficiency
    Journal Article

    Patel, D. N.; Wakeam, E.; Genoff, M.; Mujawar, I.; Ashley, S. W.; Diamond, L. C.
    Journal of Surgical Research (2016)

    Fulltext@MSK | Save
  • Interim PET evaluation by Deauville criteria is an effective risk stratification tool in PTCL
    Meeting Abstract

    Mehta-Shah, N.; Ito, K.; Bantilan, K. S.; Moskowitz, A. J.; Sauter, C. S.; Horwitz, S. M.; Schoder, H.
    Blood (2016)

    Fulltext@MSK | Save
  • Pembrolizumab for treatment of relapsed/refractory mycosis fungoides and Sezary syndrome: Clinical efficacy in a CITN multicenter phase 2 study
    Meeting Abstract

    Khodadoust, M.; Rook, A. H.; Porcu, P.; Foss, F. M.; Moskowitz, A. J.; Shustov, A. R.; Shanbhag, S.; Sokol, L.; Shine, R.; Fling, S. P.; more...
    Blood (2016)

    Fulltext@MSK | Save
  • Brentuximab vedotin demonstrates significantly superior clinical outcomes in patients with CD30-expressing cutaneous T cell lymphoma versus physician's choice (methotrexate or bexarotene): The phase 3 alcanza study
    Meeting Abstract

    Kim, Y. H.; Whittaker, S.; Horwitz, S. M.; Duvic, M.; Dummer, R.; Scarisbrick, J. J.; Quaglino, P.; Zinzani, P. L.; Wolter, P.; Wang, Y.; more...
    Blood (2016)

    Fulltext@MSK | Save